Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib in lower-risk myelodysplastic syndromes
NCT02469415Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2015
- Primary completion
- Jun 2017
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2015; status: terminated.
02
Drugs
pacritinib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02469415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02469415.